Demonstrates novel CDK2 degradation strategy in cyclin E-dependent cancers, suggesting therapeutic advancement.
High Resolution Image Download MS PowerPoint Slide Cyclin-dependent kinase 2 (CDK2) has emerged as a critical oncogenic driver in cancers characterized by cyclin E amplification and resistance to existing cell-cycle therapies. A recent patent disclosure describes heterobifunctional degraders that selectively induce CDK degradation by recruiting E3 ligases. By eliminating rather than inhibiting CDK2, these compounds offer a promising approach to suppress tumor proliferation and overcome therapeutic resistance in cyclin E-dependent malignancies.
No takes yet. Share an insight, caveat, or question.
Renner et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: